A New DME Drug Matched Anti-VEGF on Vision: Could Retina Care Be Ready for a New Option?

New research on remigromig for diabetic macular edema (DME) could signal an important shift in retinal care. At the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, researchers presented one-year results from the BRUNELLO trial showing that remigromig achieved vision improvements that were noninferior to ranibizumab, an established anti-VEGF treatment. Unlike existing therapies, this investigational drug targets a different biological pathway involved in maintaining retinal blood vessels. Could this approach eventually offer another option for patients who struggle with persistent retinal swelling?

Table of Contents

• Why Diabetic Macular Edema Needs New Treatment Options
• BRUNELLO Trial: Remigromig Matches Anti-VEGF Vision Outcomes
• How Remigromig Works Differently From Anti-VEGF Therapy
• Safety Findings and What Must Happen Before Routine Use
• Conclusion
• Frequently Asked Questions

Why Diabetic Macular Edema Needs New Treatment Options

Diabetic macular edema (DME) develops when damaged retinal blood vessels leak fluid into the macula, the part of the eye responsible for sharp central vision. As fluid builds up, patients may experience blurred vision, difficulty reading, or problems recognizing faces.

Today, anti-VEGF injections remain a cornerstone of DME treatment. These medications block vascular endothelial growth factor, a protein that contributes to abnormal blood vessel leakage. Common treatments include ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo).

However, not every patient experiences sufficient improvement. According to Merck, up to 40% of patients have persistent disease activity after six months of treatment. Some continue to experience retinal swelling despite repeated injections, while others develop recurring symptoms.

Furthermore, frequent appointments can create challenges for patients who need ongoing care. Treatment success depends not only on improving eyesight but also on maintaining those improvements over time.

Previous research covered by Diabetes in Control on ranibizumab treatment highlights the importance of preserving vision and daily functioning.

Consequently, researchers continue exploring treatments that address retinal damage through mechanisms beyond VEGF inhibition.

BRUNELLO Trial: Remigromig Matches Anti-VEGF Vision Outcomes

The phase 2b/3 BRUNELLO study evaluated the effectiveness and safety of remigromig (MK-3000), previously known as EYE103. Investigators enrolled 984 adults with diabetic macular edema and randomly assigned them to three treatment groups.

Participants received monthly eye injections of either remigromig 0.5 mg, remigromig 0.8 mg, or ranibizumab 0.5 mg.

The primary goal was to determine whether remigromig could achieve visual improvements within a predefined acceptable margin compared with ranibizumab after 52 weeks.

The findings presented at AAO 2026 were encouraging.

Average visual acuity improvement at one year:

• Remigromig 0.5 mg: 9.1 letters gained
• Remigromig 0.8 mg: 8.7 letters gained
• Ranibizumab 0.5 mg: 11.8 letters gained

Both remigromig doses met the study's primary noninferiority endpoint. This means the differences in vision improvement remained within the trial's predefined margin.

Importantly, noninferiority does not mean the drugs produced identical results. Ranibizumab showed numerically greater average letter gains, and remigromig did not demonstrate superiority on the key secondary measures.

Nevertheless, the findings suggest that a therapy targeting a different retinal pathway can produce meaningful visual improvements.

The official Merck BRUNELLO announcement provides additional information about the study design and clinical outcomes.

How Remigromig Works Differently From Anti-VEGF Therapy

One of the most promising aspects of remigromig as a potential treatment for diabetic macular edema is how differently it works from existing therapies.

Traditional anti-VEGF medications reduce the activity of proteins that promote vascular leakage and abnormal blood vessel growth. Remigromig instead activates the Wingless-related integration site pathway, commonly called the Wnt pathway.

This biological signaling system helps maintain the blood-retinal barrier, which controls the movement of fluid between blood vessels and retinal tissue.

Think of this barrier as a protective seal around delicate retinal structures. When diabetes damages the seal, fluid can escape and interfere with vision.

Rather than directly blocking VEGF, remigromig is designed to support the biological processes involved in repairing and maintaining that barrier.

Additionally, remigromig is a tri-specific antibody, meaning it interacts with multiple molecular targets to activate the pathway.

This difference raises an important possibility: future treatments might address retinal fluid through complementary mechanisms.

For example, researchers may eventually investigate whether Wnt-based therapies can work alongside anti-VEGF medications. However, combination benefits have not been established by the BRUNELLO findings.

Although the new mechanism is promising, it does not automatically translate into better clinical outcomes or fewer injections.

Safety Findings and What Must Happen Before Routine Use

Despite the positive vision results, BRUNELLO also identified safety findings that deserve careful attention.

Adverse events associated with proliferative diabetic retinopathy (PDR), including signs of abnormal retinal blood vessel growth, occurred more frequently among remigromig-treated participants.

Reported rates were 6.7% with remigromig 0.5 mg, 6.1% with remigromig 0.8 mg, and 0.9% with ranibizumab.

Furthermore, discontinuations due to adverse events occurred in approximately 4.5% to 4.9% of remigromig recipients, compared with 0.9% of ranibizumab recipients.

These differences matter because proliferative diabetic retinopathy can threaten vision and require additional treatment.

Researchers have suggested that the pattern may relate to remigromig's lack of direct VEGF inhibition. Nevertheless, additional analysis is necessary to establish the explanation and determine which patients might face increased risks.

Encouragingly, intraocular inflammation rates were low, and investigators reported no retinal vasculitis in the trial.

Another unanswered question concerns treatment frequency. During the first year, participants received injections every four weeks. Therefore, BRUNELLO has not yet established whether remigromig can reduce the injection burden compared with existing therapies.

In the second year, dosing intervals will be adjusted using a personalized treatment approach.

Meanwhile, the companion phase 2b/3 BAROLO trial is expected to provide additional evidence about effectiveness and safety.

Until more evidence becomes available and regulatory authorities complete their reviews, remigromig remains investigational rather than an established treatment option.

For patients seeking background on eye complications, Diabetes in Control's review of diabetic retinopathy offers additional context on retinal disease and monitoring.

Conclusion

The BRUNELLO findings mark an important development in diabetic eye disease research. A therapy activating the Wnt pathway demonstrated noninferior visual improvements compared with an established anti-VEGF treatment in a pivotal DME study.

However, the higher rates of proliferative diabetic retinopathy-related events, unanswered questions about long-term safety, and uncertainty surrounding treatment frequency remain significant considerations.

For now, anti-VEGF therapies remain central to DME management. Still, remigromig could eventually broaden treatment choices if further studies confirm a favorable benefit-risk profile.

Ultimately, the value of this new approach will depend on whether it can deliver reliable, lasting improvements while protecting patients from additional retinal complications.

Frequently Asked Questions

1. How does remigromig work to treat diabetic macular edema?

Remigromig is an investigational antibody treatment designed to activate the Wnt pathway, which helps maintain the blood-retinal barrier. Researchers are evaluating whether it can improve vision in people with diabetic macular edema.

2. Was remigromig as effective as ranibizumab in BRUNELLO?

Both studied doses met the trial's noninferiority endpoint at 52 weeks. However, ranibizumab produced numerically greater average vision gains, and remigromig did not demonstrate superiority.

3. Is remigromig safer than anti-VEGF injections?

The current evidence does not establish that remigromig is safer. BRUNELLO reported higher rates of proliferative diabetic retinopathy-related adverse events and treatment discontinuations in the remigromig groups.

4. Will remigromig require fewer eye injections?

That remains unknown. During the first year of BRUNELLO, all treatment groups received monthly injections. Longer-term results will help clarify whether treatment intervals can be extended.

5. Is remigromig available for patients with diabetic macular edema?

As of October 2026, remigromig remains an investigational therapy and is not an approved routine DME treatment. Patients should discuss available options with their retinal specialist. For additional help finding healthcare guidance, visit Healthcare.pro.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.